QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.061762v1 309/3/1248    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McMillan, D. E. Articles by Owens, S. M. Search for Related Content PubMed PubMed Citation Articles by McMillan, D. E. Articles by Owens, S. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB d-METHAMPHETAMINE Medline Plus Health Information Methamphetamine

BEHAVIORAL PHARMACOLOGY

Effects of Murine-Derived Anti-Methamphetamine Monoclonal Antibodies on (+)-Methamphetamine Self-Administration in the Rat

Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas (D.E.M., W.C.H., M.L., M.G.G., S.M.O.); and Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina (F.I.C., P.A.)

Two murine-derived anti-methamphetamine monoclonal antibodies were studied as potential pharmacokinetic antagonists of (+)-methamphetamine self-administration by rats. Intravenous administration of a 1 g/kg dose of the lower affinity [antibody equilibrium dissociation constant (K_d) = 250 nM] monoclonal antibody (mAb) designated mAb6H8, 1 day before the start of several daily 2-h self-administration sessions produced effects that depended on the dose of (+)-methamphetamine. mAb6H8 increased the rate of self-administration of a unit dose of 0.06 mg/kg (+)-methamphetamine, had little effect on the rate of self-administration of a unit dose of 0.03 mg/kg (+)methamphetamine, and lowered the rate of self-administration of a unit dose of 0.01 mg/kg (+)-methamphetamine to a level similar to that after saline substitution. mAb-induced changes in rates of self-administration occurred very early in self-administration sessions and lasted for 3 to 7 days. Intravenous administration of a 1 or a 0.6 g/kg dose of a higher affinity (K_d = 11 nM) mAb designated mAb6H4, 24 h before the first of several self-administration sessions, produced very similar effects to the lower affinity mAb, despite the more than 20-fold greater affinity for (+)-methamphetamine. It is proposed that these anti-methamphetamine antibodies bind some of the self-administered (+)-methamphetamine before it can penetrate into brain, thereby reducing the amount of free drug available to function as a reinforcer. Although neither of these mAb medications are optimal antibodies for treating (+)-methamphetamine abuse, the experiments demonstrate that anti-(+)-methamphetamine monoclonal antibodies can attenuate the self-administration of the drug and suggest the potential of using monoclonal antibodies as pharmacokinetic antagonists of (+)-methamphetamine.

Address correspondence to: D.E. McMillan, Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72204. E-mail: DEMcMillan{at}uams.edu

This article has been cited by other articles:

				A. B. Norman, M. K. Norman, W. R. Buesing, M. R. Tabet, V. L. Tsibulsky, and W. J. Ball The Effect of a Chimeric Human/Murine Anti-Cocaine Monoclonal Antibody on Cocaine Self-Administration in Rats J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 873 - 881. [Abstract] [Full Text] [PDF]

				S. A. Roiko, A. C. Harris, D. E. Keyler, M. G. LeSage, Y. Zhang, and P. R. Pentel Combined Active and Passive Immunization Enhances the Efficacy of Immunotherapy against Nicotine in Rats J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 985 - 993. [Abstract] [Full Text] [PDF]

				E. C. Peterson, M. Gunnell, Y. Che, R. L. Goforth, F. I. Carroll, R. Henry, H. Liu, and S. M. Owens Using Hapten Design to Discover Therapeutic Monoclonal Antibodies for Treating Methamphetamine Abuse J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 30 - 39. [Abstract] [Full Text] [PDF]

				D. E. Keyler, S. A. Roiko, E. Benlhabib, M. G. LeSage, J. V. St. Peter, S. Stewart, S. Fuller, C. T. Le, and P. R. Pentel MONOCLONAL NICOTINE-SPECIFIC ANTIBODIES REDUCE NICOTINE DISTRIBUTION TO BRAIN IN RATS: DOSE- AND AFFINITY-RESPONSE RELATIONSHIPS Drug Metab. Dispos., July 1, 2005; 33(7): 1056 - 1061. [Abstract] [Full Text] [PDF]